Human papillomavirus (HPV) is the world’s most common sexually transmitted infection and is strongly associated with the development of cervical cancer in women and other health conditions in both sexes. Professor Matt Keeling led a programme with colleagues in Warwick Medical School to assess cost effectiveness of a gender-neutral HPV vaccination campaign.
Based on the recommendations from the Warwick model, the Joint Committee on Vaccination and Immunisation (JCVI) recommended extending the HPV vaccination programme to include adolescent boys for the first time. From September 2019 - March 2020, gender-neutral HPV vaccination started in 83% of local authorities in England. The switch to a gender-neutral national policy on vaccination against HPV in the UK is predicted over the next 50 years to lead to the prevention of approximately:
- 5800 cases of oropharyngeal cancer
- 4000 cases of cervical cancer
- 2000 cases of anal cancer
- 1000 cases of penile cancer
- 25,000 cases of cervical intraepithelial neoplasia
- 230,000 cases of genital warts.
https://warwick.ac.uk/research/impact/science/mathematics/hpv
